Yvonne Greenstreet sold $4.0M of ALNY
Chief Executive Officer at ALNYLAM PHARMACEUTICALS, INC.. 8,924 shares at an average of $452.05, traded Oct 2, 2025, filed Oct 3, 2025.
Score components
- +25RoleCEO
- +25Trade size$4.0M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster5 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000116, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2025 | AGrant or award Common Stock | +3,860 | $0.00 | $0 | 60,081 | Oct 3, 2025 |
| Oct 1, 2025 | AGrant or award Common Stock | +14,252 | $0.00 | $0 | 74,333 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -350 | $446.53 | $156k | 73,983 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -171 | $447.92 | $77k | 73,812 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -548 | $448.77 | $246k | 73,264 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -758 | $449.79 | $341k | 72,506 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -1,642 | $450.81 | $740k | 70,864 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -1,010 | $451.86 | $456k | 69,854 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -2,029 | $452.69 | $919k | 67,825 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -999 | $453.77 | $453k | 66,826 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -741 | $454.84 | $337k | 66,085 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -221 | $455.82 | $101k | 65,864 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -446 | $457.43 | $204k | 65,418 | Oct 3, 2025 |
| Oct 2, 2025 | SOpen-market sale Common Stock | -9 | $457.64 | $4,119 | 65,409 | Oct 3, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.